QURE
Uniqure N.v. Health Care Pharmaceutical Preparations Russell 3000
$24.83Close
$1.5BMarket cap
$9.03 – $67.8652-week range
Nov 4, 2026Next report · before the open
Highlights
Cautions
- Not in an uptrend 3 of 8 trend conditions
- Lagging the market RS 13 · weaker than 87% of stocks over 12 months
- Far from its high 63% below its 52-week high
- Distribution down-day volume 2.7× up-day volume over 50 sessions
- Results soon Nov 4, 2026, in 3 days
- Financial distress Altman Z″ in the distress zone
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
63%
1wk
up 10.7%
price change
1mo
up 2.8%
price change
12-month return
down 63%
market up 11% ·
its own down 76%
F-score
2 / 9
Weak
Altman Z
-0.63
Elevated risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
7.8×
price / book
Earnings yield
down 12.2%
EBIT / enterprise value
Cheaper than
12%
of the market · expensive
Revenue growth
down 41%
year on year
EPS growth
—
latest quarter
Sales growth
—
latest quarter
ROE
down 100%
return on equity
Free cash margin
down 1108%
-$178.4M FCF
D/E
0.25
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Piotroski tests
- not yet profitable on its assets
- operating cash flow is negative
- profitability slipped from last year
- took on more long-term debt
- issued more shares
- gross margin narrowed
- assets working less efficiently
- profits backed by cash
- short-term liquidity improved
Trade setup
ATR%
7.1%
$1.77 a day · 2×ATR $21.30
RS
13 / 99
vs the universe
Trend
3 / 8
trend template
Relative volume
0.8×
vs 50-day average
Up/down volume
0.37
50 sessions
Implied move
—
no option chain · report Nov 4, 2026
Trend template · 3 of 8
- Price above the 150 and 200-day averages: fails
- 150-day average above the 200-day: passes
- 200-day average rising for a month: fails
- 50-day average above the 150 and 200-day: passes
- Price above the 50-day average: fails
- At least 30% above the 52-week low: passes
- Within 25% of the 52-week high: fails
- RS rank 70 or higher: fails
Screen verdict
Did not qualify for any screen.
Warning signs
- Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
- Shareholders diluted The share count rose 27.2% over the year, from 49m to 62m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
- Gross margin narrowing Gross margin fell from 95.3% to 89.5%. The company is keeping less of each dollar of sales than it did a year ago.
- Revenue shrinking Revenue fell 40.6% over the year, from $27.1M to $16.1M.
Last reported
Jul 29, 2026
Last shock
Sep 29, 2026-37% in one session15.5× volumeon an SEC filing+1% since
Financials
- Gross 90%
- Net -1236%
- Free cash -1108%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $37.5M | $524.0M | $106.5M | $15.8M | $27.1M | $16.1M |
| Gross margin | 92% | 95% | 99% | 100% | 95% | 90% |
| Operating income | -$125.4M | $310.6M | -$143.2M | -$282.9M | -$184.3M | -$185.3M |
| Net income | -$125.0M | $329.6M | -$126.8M | -$308.5M | -$239.6M | -$199.0M |
| Net margin | -333% | 63% | -119% | -1947% | -884% | -1236% |
| Earnings per share | -$2.81 | $7.04 | -$2.71 | -$6.47 | -$4.93 | -$3.46 |
| Free cash flow | -$142.1M | $270.5M | -$162.7M | -$153.1M | -$186.1M | -$178.4M |
| Free cash margin | -379% | 52% | -153% | -966% | -686% | -1108% |
| Cash | $244.9M | $556.3M | $228.0M | $241.4M | $158.9M | $80.2M |
| Long-term debt | $35.6M | $101.0M | $102.8M | $101.7M | $51.3M | $49.7M |
| Shareholders' equity | $243.9M | $595.8M | $476.0M | $207.7M | -$6.8M | $198.9M |
| Shares outstanding | 44.78m | 46.30m | 46.97m | 47.83m | 48.99m | 62.34m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| May 5, 2026 | Quarterly ↗ | Mar 31, 2026 | 35d |
| Mar 2, 2026 | Annual ↗ | Dec 31, 2025 | 61d |
| Nov 10, 2025 | Quarterly ↗ | Sep 30, 2025 | 41d |
| Jul 29, 2025 | Quarterly ↗ | Jun 30, 2025 | 29d |
| May 9, 2025 | Quarterly ↗ | Mar 31, 2025 | 39d |
| Feb 27, 2025 | Annual ↗ | Dec 31, 2024 | 58d |
| Nov 5, 2024 | Quarterly ↗ | Sep 30, 2024 | 36d |
| Aug 1, 2024 | Quarterly ↗ | Jun 30, 2024 | 32d |
| May 7, 2024 | Quarterly ↗ | Mar 31, 2024 | 37d |
| Feb 28, 2024 | Annual ↗ | Dec 31, 2023 | 59d |
| Nov 7, 2023 | Quarterly ↗ | Sep 30, 2023 | 38d |
| Aug 1, 2023 | Quarterly ↗ | Jun 30, 2023 | 32d |
Current reports
| Filed | Disclosed |
|---|---|
| Sep 29, 2026 | Regulation FD ↗ |
| Sep 2, 2026 | Regulation FD ↗ |
| Jul 29, 2026 | Results ↗ |
| Jun 24, 2026 | Material agreement · Other events ↗ |
| Jun 22, 2026 | Regulation FD · Other events ↗ |
| Jun 17, 2026 | Other events ↗ |
| Jun 15, 2026 | Director or officer change · Charter or bylaws · Shareholder vote ↗ |
| May 5, 2026 | Results ↗ |
| Apr 30, 2026 | Regulation FD ↗ |
| Mar 2, 2026 | Results · Regulation FD ↗ |
| Jan 13, 2026 | Regulation FD ↗ |
| Jan 9, 2026 | Regulation FD ↗ |